Laurion Capital Management LP Aldeyra Therapeutics, Inc. Transaction History

Laurion Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $316,231 - $528,831	44,477 Added 4.65%	1,001,377 $8.4 Million
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $56,547 - $115,178	-14,881 Reduced 1.53%	956,900 $5.11 Million
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $2.36 Million - $4.71 Million	971,781 New	971,781 $3.88 Million
Q4 2018 Feb 14, 2019	SELL	$7.26 - $13.29 $1.45 Million - $2.66 Million	-200,000 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$6.8 - $14.35 $1.36 Million - $2.87 Million	200,000 New	200,000 $2.76 Million

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $298M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.